Markets

CHMP Positive on Ariad's Iclusig - Analyst Blog

A generic image of stock metrics
Credit: Shutterstock photo

Ariad Pharmaceuticals Inc. ( ARIA ) recently announced that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has given a favorable opinion on the marketing authorization application for Iclusig. Ariad is looking to get Iclusig approved for two indications.

The first indication relates to the treatment of adults suffering from chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant and intolerant to Bristol-Myers Squibb Company 's ( BMY ) Sprycel (dasatinib) or Novartis AG 's ( NVS ) Tasigna (nilotinib). For these patients, subsequent treatment with Novartis' Glivec (imatinib) is considered clinically inappropriate or they have the T3151 mutation.

The second indication relates to the treatment of adults suffering from Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL), and who are resistant and intolerant to Sprycel. Subsequent treatment with Glivec is not considered clinically appropriate for these patients or they also have the T3151 mutation.

A final verdict on the approval of status Iclusig by the EMA is expected in mid-2013.

We remind investors that Iclusig is already approved in the US. On Dec 14, 2012, Ariad announced that Iclusig gained US Food and Drug Administration (FDA) approval for the treatment of CML and Ph+ALL in patients resistant or intolerant to prior tyrosine kinase inhibitor therapy.

We are encouraged by the positive CHMP recommendation for Iclusig. With the CHMP issuing a positive opinion, we believe chances of gaining EU approval are high. We expect investor focus to remain on the EU approvability status and the commercialization of Iclusig in the US.

Currently, Ariad carries a Zacks Rank #3 (Hold). Other biotech stocks that look better-positioned than Ariad include Cytokinetics, Inc. ( CYTK ). Cytokinetics presently carries a Zacks Rank #1 (Strong Buy).

ARIAD PHARMA (ARIA): Free Stock Analysis Report

BRISTOL-MYERS (BMY): Free Stock Analysis Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CYTK BMY NVS

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More